Disc Medicine Appoints Will Savage, MD, PhD as Medical Director and Jonathan Yu as Commercial Director and Extends Scientific Leadership with Key Hires to Advance Pipeline to Clinical Stage
CAMBRIDGE, Mass., 23 Aug 2021 / PRNewswire / – Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of severe and debilitating hematologic diseases, today announced the promotion of Will savage, MD, PhD to Chief Medical Officer and Jonathan yu to the sales manager. In addition, the company expanded its scientific leadership with the appointment of industry veterans Hua Yang, PhD, as vice president of non-clinical development and clinical pharmacology and Sarah tuller, JD as vice president of regulatory affairs.
“We are entering an exciting chapter in the history of the record and I am delighted that we have attracted a team whose leadership and in-depth experience will allow us to create a business that will make a difference in the lives of patients,” said Jean Quisel, JD, PhD, CEO of Disc Medicine. “I want to congratulate Will and Jonathan on their respective promotions and welcome Hua and Sarah to the company. I am excited to work with this team as we advance our clinical stage pipeline deep into development.
Dr Hua Yang, PhD, is Vice President of Non-Clinical Development and Clinical Pharmacology and brings over 20 years of experience in drug discovery, non-clinical development and clinical pharmacology. Prior to Disc, she was Vice President of DMPK and Clinical Pharmacology at Agios Pharmaceuticals, where she established these roles and was instrumental in the discovery, development and successful approvals of its flagship IDHIFA® (enasidinib ) in relapsed or refractory AML. and TIBSOVO® (ivosidenib) in AML patients with IDH1 mutations, as well as mitapivat (PKR activator) and vorasidenib (dual IDH1 / 2 inhibitor). Prior to Agios, Hua held positions in DMPK and Drug Discovery at Millennium / Takeda Pharmaceuticals and Bristol-Myers Squibb. Hua received her BA in Pharmacology from Fudan University, MA in Pharmacology from Peking Union Medical School, and her PhD. in Pharmacokinetics of University of Nebraska Medical Center. She is the co-inventor of more than 50 patent applications.
Sarah tuller, JD, RAC is Vice President of Regulatory Affairs and brings 20 years of experience in regulatory strategy and operations, covering numerous clinical and commercial stage products in a wide range of therapeutic indications, including multiple drug programs. orphan diseases. She has led or been a part of many successful IND, NDA, MAA and BLA and other submissions including those of Portrazza® (necitumumab) in the treatment of metastatic, squamous, NSCLC, Phoslyra® (calcium acetate) in the IRT and Avonex Pen® (interferon beta-1a) in relapsing MS. Prior to joining Disc, she held leadership roles in regulatory affairs for rare disease programs at Astellas Pharma, and prior to Astellas, at companies such as Biogen, Fresenius and Baxter. Sarah holds a JD from the University of Dayton Faculty of Law and a bachelor’s degree in chemistry.
Disc recently announced the launch of a Phase 1 clinical study of DISC-0974, a first-class hemojuvelin (HJV) inhibitor designed to suppress hepcidin and is in development to treat several forms of anemia. inflammatory. The company plans to initiate clinical studies of a separate program in early 2022 for bitopertin, a first-class GlyT1 inhibitor that is being developed to treat erythropoietic porphyrias, a family of serious, genetic and rare hematologic disorders.
About disc medicine
Disc Medicine is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with blood disorders. We are building a unique portfolio of innovative and first-class therapeutic candidates based on fundamental pathways in red blood cell biology. Disc Medicine is committed to building a better future for patients who suffer from hematologic diseases, ranging from serious orphan conditions to widespread illnesses. For more information, please visit www.discmedicine.com.
SOURCE Medicine Disc